World

WHO announces start of Ebola vaccine clinical trial in DR Congo

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 24/10/2026, 00:56:23 UTC.

Briefings

WHO announced the start of a clinical trial in DR Congo to test multiple Ebola vaccine candidates for safety, efficacy, and immunogenicity. The trial began on October 24, 2026, marking a significant step in global efforts to combat the virus. This initiative represents a major expansion of the global response to the outbreak.

Key points

• WHO launched a clinical trial in DR Congo to evaluate multiple Ebola vaccine candidates for safety, efficacy, and immunogenicity.
• The trial commenced on October 24, 2026, involving multiple vaccine types to assess their potential against the Ebola virus.

Context

This trial is part of WHO's broader strategy to develop and deploy vaccines against Ebola, a critical step in the global response to the ongoing outbreak in the region.

Limitations

The evidence is limited to the announcement of the trial's start date and scope. Specific details on the number of participants, vaccine types tested, or expected outcomes are not provided in the source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 24/10/2026, 00:57:08 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihygf65nlws6yikos5qb7ebyy6elcw25b7ytgotdl5cbrwkso2dte